about
Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis.Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care ProvidersPimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsConsequences of seven novel mutations on the expression and structure of keratinocyte transglutaminase.Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew.Carbohydrate-carbohydrate binding of ganglioside to integrin alpha(5) modulates alpha(5)beta(1) function.A novel KIT mutation results in piebaldism with progressive depigmentation.Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population.Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.Epidermolytic Ichthyosis Sine EpidermolysisGanglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptor-Rac1 Activation to Inhibit Keratinocyte Motility.Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009.Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation.Activated STING in a vascular and pulmonary syndromeThe genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes.Multifunctional skin-like electronics for quantitative, clinical monitoring of cutaneous wound healing.Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia congenita type 2.Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids.Phenotype of atopic dermatitis subjects with a history of eczema herpeticum.Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosaMethylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD.Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology.Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.Prevalence and characterization of pruritus in epidermolysis bullosa.Genetic disorders of skin: a decade of progress.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.Proceedings of the Inaugural Pediatric Dermatology Research Alliance (PeDRA) conference.Pathogenesis-based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolismFrequent somatic reversion of KRT1 mutations in ichthyosis with confetti.Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.Excess adiposity preceding pediatric psoriasis.siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approachesVisualization of Sensory Neurons and Their Projections in an Upper Motor Neuron Reporter Line.Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.Mutations in the glycosylphosphatidylinositol gene PIGL cause CHIME syndrome.
P50
Q24532794-06185C5D-BB43-4F46-AB28-35E6EDFE5C04Q26799376-E9CA095A-C0CF-4911-BE86-4D7D8DE2E045Q28086973-586C0DF0-EF9B-4D79-B194-0A43204808ADQ30176425-37F8EDBC-18E0-441B-9D67-FB5AF342E4D1Q30887050-26644CB5-26AA-4897-A199-27025DF286F5Q31705382-7595597B-AC25-45BE-86F3-6D0459AE8424Q31928241-99C8A249-F3A7-4684-83EB-366C9D3B0620Q31928462-ADF83C4F-E341-4A6A-9D20-097C2F0EAD70Q33186561-FFC20DA8-7CCD-4E90-A2CE-9BDB6AC070A2Q33694649-CA3383CA-4F2E-4A37-9D87-C30D69C188E8Q33850381-D01A02C5-3C92-497D-BED9-19716A8B06C1Q33878505-F913C7AA-31A1-4256-971F-95B29F06AF57Q34126886-6A10707C-ECF7-46F2-A5BE-11332B9AD6D0Q34179586-77D09F83-6D6A-42EA-940E-0126AA076E56Q34241214-5C58A96D-CBAA-4B01-9C1A-4D57FD69A2A9Q34250258-1026802D-0E58-4698-8D06-C06DA95D8F13Q34253064-FA887307-ACB9-44D5-9287-A63F473EF462Q34364694-923A3B44-3CFB-4AD7-95A5-924037F292DAQ34388802-A0530ED2-CC3D-41F5-AE2E-6222AEE78742Q34434200-2464CA8B-E78C-4530-BE1F-3FEFC55C3917Q34474736-86F4396F-D69F-42A6-9592-1CB1DB57475EQ34478009-4F6404C3-FD2F-4FB3-93F1-D727420DFD67Q34663953-0F3DD544-11BD-4AA0-B7CD-E29E5EE82FC0Q34700774-DE9787CC-4283-474F-81D0-933349B0552CQ34743102-C8E24D78-5142-4669-881A-EE99EDEE75B6Q34760948-9C0A4CA8-E080-48A0-B7AB-130D46D3491CQ34978393-61778F3C-79B6-41E3-912B-6AA552FD184FQ35044311-9B57AE5F-9321-442E-ACA0-7D56CDFCF55BQ35047665-0B967F52-76B2-4012-B093-DFE41AA2F017Q35077866-F6A21629-6814-46AB-92DE-7DEB10A0E9C7Q35149699-F2E57B9A-ED05-471C-9A77-7A53F5C5232DQ35350057-9EAFC963-C5B3-4C09-A4EA-539EEC6BFF85Q35409123-2A295BFA-1C2F-4509-877D-9E692FD0379CQ35539576-5A15BDDC-A961-47F7-8CD7-F8D66FAD9729Q35589113-DDBAB9AB-4AE4-4F0F-80FC-4A24BA1779FFQ35590281-30078F88-365A-435E-8E93-601822E81E2AQ35603170-EE6504A2-359D-47A0-B42F-CC5BDB5B57DAQ35723883-22169216-C10F-4693-BE92-453207AE1A8EQ35754152-9DF9E847-00E8-4124-91A4-EE7D064176AAQ35877816-817905DF-B597-425E-9022-37DD6E8824C8
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Amy S Paller
@nl
Amy S Paller
@sl
Amy S. Paller
@en
Amy S. Paller
@es
type
label
Amy S Paller
@nl
Amy S Paller
@sl
Amy S. Paller
@en
Amy S. Paller
@es
prefLabel
Amy S Paller
@nl
Amy S Paller
@sl
Amy S. Paller
@en
Amy S. Paller
@es
P214
P106
P1153
16750923100
P21
P214
P31
P496
0000-0001-6187-6549
P735
P7859
viaf-238565896